File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Practical management of natural killer/T-cell lymphoma

TitlePractical management of natural killer/T-cell lymphoma
Authors
Issue Date2012
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-oncology.com
Citation
Current Opinion in Oncology, 2012, v. 24 n. 5, p. 480-486 How to Cite?
AbstractPURPOSE OF REVIEW: Natural killer (NK)/T-cell lymphoma is a distinct clinic-pathological entity in the WHO classification of lymphoid neoplasms. It is uncommon among all lymphomas but is more prevalent in Asian countries. The pathogenesis remains unknown despite its strong association with Epstein-Barr virus (EBV) infection. Conventional chemotherapeutic regimens such as CHOP do not appear to be effective and the prognosis is dismal especially in advanced-stage disease. The major objective of this review will focus on the practical management of patients with NK/T-cell lymphoma especially on the treatment using L-asparaginase-based regimen. Data on gene and micro-RNA expression profiling studies are also discussed which may impact the development of new drugs targeting specific oncogenic pathways. RECENT FINDINGS: Gene expression profiling and other genetic studies have revealed distinct oncogenic signalling pathway activation and have identified potential targets for therapeutic intervention in NK/T-cell lymphoma. Quantitative measurement of EBV-DNA in cell-free plasma, rather than cellular EBV-DNA level predicts overall survival as shown by a recent prospective study. L-Asparaginase-based chemotherapeutic regimens such as SMILE and AspaMetDex have been demonstrated to be highly effective in the treatment of advanced-stage and relapsed/refractory disease. SUMMARY: An accurate histopathological diagnosis and precise staging using PET computed tomography (PET-CT) scan are essential in the management of patients with NK/T-cell lymphoma. Recent prospective trials have demonstrated that L-asparaginase-based chemotherapeutic regimen is highly effective and improves outcome of patients with locally advanced as well as disseminated disease. The impact of haematopoietic stem cell transplantation remains to be defined.
Persistent Identifierhttp://hdl.handle.net/10722/164301
ISSN
2015 Impact Factor: 4.614
2015 SCImago Journal Rankings: 1.890
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTse, Een_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-20T07:57:46Z-
dc.date.available2012-09-20T07:57:46Z-
dc.date.issued2012en_US
dc.identifier.citationCurrent Opinion in Oncology, 2012, v. 24 n. 5, p. 480-486en_US
dc.identifier.issn1040-8746-
dc.identifier.urihttp://hdl.handle.net/10722/164301-
dc.description.abstractPURPOSE OF REVIEW: Natural killer (NK)/T-cell lymphoma is a distinct clinic-pathological entity in the WHO classification of lymphoid neoplasms. It is uncommon among all lymphomas but is more prevalent in Asian countries. The pathogenesis remains unknown despite its strong association with Epstein-Barr virus (EBV) infection. Conventional chemotherapeutic regimens such as CHOP do not appear to be effective and the prognosis is dismal especially in advanced-stage disease. The major objective of this review will focus on the practical management of patients with NK/T-cell lymphoma especially on the treatment using L-asparaginase-based regimen. Data on gene and micro-RNA expression profiling studies are also discussed which may impact the development of new drugs targeting specific oncogenic pathways. RECENT FINDINGS: Gene expression profiling and other genetic studies have revealed distinct oncogenic signalling pathway activation and have identified potential targets for therapeutic intervention in NK/T-cell lymphoma. Quantitative measurement of EBV-DNA in cell-free plasma, rather than cellular EBV-DNA level predicts overall survival as shown by a recent prospective study. L-Asparaginase-based chemotherapeutic regimens such as SMILE and AspaMetDex have been demonstrated to be highly effective in the treatment of advanced-stage and relapsed/refractory disease. SUMMARY: An accurate histopathological diagnosis and precise staging using PET computed tomography (PET-CT) scan are essential in the management of patients with NK/T-cell lymphoma. Recent prospective trials have demonstrated that L-asparaginase-based chemotherapeutic regimen is highly effective and improves outcome of patients with locally advanced as well as disseminated disease. The impact of haematopoietic stem cell transplantation remains to be defined.-
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-oncology.comen_US
dc.relation.ispartofCurrent Opinion in Oncologyen_US
dc.rightsThis is a non-final version of an article published in final form in (Current Opinion in Oncology, 2012, v. 24 n. 5, p. 480-486)-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshAsparaginase - administration and dosage-
dc.subject.meshGene Expression Profiling-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Extranodal NK-T-Cell - diagnosis - drug therapy - genetics - pathology-
dc.titlePractical management of natural killer/T-cell lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailTse, E: ewctse@hku.hken_US
dc.identifier.emailKwong, YL: ylkwong@hku.hken_US
dc.identifier.authorityTse, EWC=rp00471en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/CCO.0b013e3283556142-
dc.identifier.pmid22691924-
dc.identifier.scopuseid_2-s2.0-84865505741-
dc.identifier.hkuros207788en_US
dc.identifier.volume24en_US
dc.identifier.issue5en_US
dc.identifier.spage480en_US
dc.identifier.epage486en_US
dc.identifier.eissn1531-703X-
dc.identifier.isiWOS:000307681500004-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats